The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Scientists at Duke University are actively influencing how the next generation of GLP-1 medications gets designed, tested, and approved. For patients currently taking or considering these drugs, understanding where the science is headed can help you make smarter decisions now. Here is what the research means in plain terms.
MyNetDiary has launched a dedicated GLP-1 Companion feature designed for people using semaglutide and tirzepatide medications. This article breaks down what the tool offers, how it compares to other tracking options, and whether it can genuinely help you get better results on your GLP-1 journey.
Canada has approved an additional generic version of Ozempic (semaglutide), marking a significant shift in access to one of the world's most prescribed diabetes and weight-loss medications. This article breaks down what the approval means for Canadian patients, how generic semaglutide compares to the brand-name version, and what to watch for as the market evolves.
A new cohort study found no significant link between GLP-1 medication use around the time of pregnancy and hypertensive disorders. This is important news for women of childbearing age who are using or considering semaglutide or tirzepatide. Here is what the findings mean in plain terms and what you should discuss with your doctor.
When celebrity weight loss sparks Ozempic rumors, the real conversation gets buried. Here's what actually matters for patients considering semaglutide, from medical eligibility to costs and realistic expectations.
Rosie O'Donnell recently shared she has lost nearly 60 pounds using Mounjaro since relocating to Ireland. Her story raises important questions about tirzepatide access, real-world results, and what patients in the US should know before starting this medication.
Novo Nordisk is rebranding Rybelsus, its oral semaglutide tablet, under the Ozempic name. This move has real implications for patients comparing GLP-1 options. Here is what you need to know before your next provider conversation.
The FDA is taking action to limit compounded versions of popular GLP-1 medications like semaglutide and tirzepatide, citing safety concerns. If you're currently using a compounded GLP-1 or weighing your options, this shift has real implications for your treatment plan and your wallet. Here's what you need to know.
